Week in Review: MID Labs Raises $51 Million from China Investors

MID Labs, a California company that develops novel vitreoretinal surgery devices, closed a $51 million funding from China investors, led by OrbiMed and Frontline BioVentures; Invitae Corporation of San Francisco raised $120 million to support its 218 gene test in a Series F round that included Shanghai-based Decheng Capital; Sihuan Pharma will collaborate with China's Academy of Military Medical Sciences to develop an anti-adenovirus drug; Fosun Intl. paid $607 million to buy a 51% stake in Espirito Santo Saude, a chain of Portuguese healthcare services; BravoVax of China in-licensed a rotavirus vaccine from the International Medica Foundation that is approved for newborns; Hangzhou Joinstar and Response Biomedical of Canada will co-develop multiple assays to run on Joinstar's high throughput rapid immunoassay analyzer; Yew Bio-Pharm Group, a Harbin company, will distribute a medical device in China that treats carpal tunnel syndrome; and Sihuan Pharma said its newly acquired Ebola treatment, JK-05, could file for China approval by year-end if the drug is fast-tracked under CFDA green-light rules. More details.... Stock Symbols: (HK: 0460) (HK: 656) (SHA: 600079) (TSX: RBM; OTCBB: RPBIF) (OTCBB: YEWB) (HK: 460) Share this with colleagues: // //